Imagine walking into a clinic with treatment-resistant depression and walking out the same day with a complete course of therapy that typically takes weeks to complete. This isn’t science fiction—it’s the reality of ONE-D TMS, a revolutionary protocol that’s transforming how we approach depression treatment.
Traditional transcranial magnetic stimulation (TMS) requires patients to commit to 36 sessions over nine weeks. For many people struggling with depression, this schedule creates insurmountable barriers. But what if an entire course of TMS could be delivered safely and effectively in just one day?
That’s exactly what ONE-D (Optimized, Neuroplasticity-Enhanced Depression) TMS accomplishes. This groundbreaking protocol compresses weeks of treatment into approximately 12-13 hours, delivering remarkable results that rival—and often exceed—traditional approaches.
How ONE-D Revolutionizes TMS Treatment
The ONE-D protocol represents a fundamental shift in TMS delivery. Instead of spreading treatment across weeks, patients receive 20 sessions of intermittent theta burst stimulation (iTBS) in a single day, with each session lasting just three minutes and spaced 30 minutes apart.
This approach leverages several key scientific advances:
Intermittent Theta Burst Stimulation: Unlike traditional TMS sessions that last 30-40 minutes, iTBS delivers the same therapeutic benefit in just three minutes. This dramatic reduction in session time makes multiple daily treatments feasible without overwhelming patients.
Neuroplasticity Enhancement: The protocol includes two medications that boost the brain’s ability to form new neural connections. Patients receive D-cycloserine (125mg) and lisdexamfetamine (20mg) one hour before treatment begins. These medications work by enhancing the brain’s natural plasticity mechanisms, making the TMS more effective.
Optimized Spacing: Research shows that 30-minute intervals between sessions allow the brain to consolidate changes from each treatment while remaining receptive to additional stimulation. This timing maximizes the cumulative effect of multiple sessions.
Clinical Outcomes That Exceed Expectations
The results from ONE-D TMS are nothing short of remarkable. In a recent real-world study of 32 patients with treatment-resistant depression:
- 90.3% response rate on depression scales
- 74.2% remission rate at six weeks
- Effects sustained at 12-week follow-up
- No serious adverse events reported
These outcomes surpass many traditional TMS protocols and rival the most advanced accelerated treatments available. Perhaps most importantly, patients begin seeing improvements within the first week, with steady progress continuing over the following six weeks.
ONE-D vs. Traditional TMS: A Clear Advantage
Traditional TMS requires significant commitment from patients. Nine weeks of daily visits create logistical challenges that prevent many people from accessing treatment. Transportation, work schedules, childcare, and other life demands make consistent attendance difficult or impossible.
ONE-D eliminates these barriers. Patients complete their entire treatment course in a single visit, making TMS accessible to:
- People living in remote areas far from treatment centers
- Busy professionals who cannot take weeks off work
- Patients with mobility limitations
- Individuals with unpredictable schedules
- Those seeking rapid intervention during crisis periods
The protocol also reduces the overall cost burden by eliminating multiple trips and allowing patients to return to their normal routines immediately after treatment.
How ONE-D Differs From SAINT Protocol
While both ONE-D and Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) deliver accelerated TMS, they take different approaches:
SAINT Protocol:
- Five days of treatment
- 10 sessions per day (50 total)
- Requires personalized brain imaging
- Shows rapid response (often within 2-3 days)
- More resource-intensive
ONE-D Protocol:
- Single day of treatment
- 20 sessions total
- Uses standardized targeting methods
- Response develops over 1-6 weeks
- More accessible and cost-effective
Both protocols achieve excellent outcomes, but ONE-D offers greater accessibility by eliminating the need for multiple treatment days and expensive brain imaging.
The Science Behind ONE-D’s Success
The effectiveness of ONE-D stems from its sophisticated understanding of neuroplasticity—the brain’s ability to reorganize and form new neural connections. Depression involves dysfunctional neural circuits, particularly in the prefrontal cortex. TMS works by stimulating these areas and promoting healthier brain activity patterns.
D-cycloserine enhances this process by acting on NMDA receptors, which play a crucial role in learning and memory formation. By boosting these receptors’ activity, D-cycloserine helps the brain form stronger, more lasting changes in response to TMS.
Lisdexamfetamine increases dopamine levels, which research suggests may enhance the brain’s plasticity response to TMS. Studies have shown that patients taking stimulant medications often show faster and stronger responses to TMS treatment.
The combination of optimized stimulation timing, neuroplasticity enhancement, and targeted brain stimulation creates a synergistic effect that maximizes therapeutic benefit in minimal time.
Safety Profile and Patient Experience
Safety was a primary concern in developing the ONE-D protocol. The treatment profile shows excellent tolerability:
- No seizures or serious adverse events
- Mild side effects limited to temporary scalp discomfort and occasional headaches
- All patients completed the full 20-session protocol
- No cognitive impairment observed
Patients spend the day at the clinic in a comfortable environment, with 30-minute breaks between sessions. Many use this time to work, read, or relax. The experience is far less disruptive than traditional treatment schedules.
Addressing Treatment-Resistant Depression
ONE-D shows particular promise for treatment-resistant depression—cases where multiple antidepressants have failed. The study population had tried an average of four different medications without success, representing the challenging cases that often exhaust traditional options.
The protocol’s high success rate in this population suggests it could become a first-line intervention for severe cases, potentially preventing the progression to more invasive treatments like electroconvulsive therapy.
Expanding Access to Life-Changing Treatment
Perhaps the most significant impact of ONE-D lies in its potential to expand access to TMS therapy. Currently, many patients who could benefit from TMS never receive it due to logistical barriers. A single-day protocol removes these obstacles, potentially helping thousands more people access this life-changing treatment.
Rural patients who previously faced hours of travel for weeks of treatment can now make one trip for complete therapy. Working professionals don’t need to negotiate extended time off. Patients with limited mobility can arrange transportation for a single day rather than months of visits.
Looking to the Future
The success of ONE-D opens exciting possibilities for TMS treatment. Researchers are already exploring whether the protocol could be further optimized—perhaps requiring fewer sessions or different medication combinations. Early evidence suggests the approach may also work for other conditions like obsessive-compulsive disorder and anxiety disorders.
As the protocol undergoes larger controlled studies, we may see it become a standard option for depression treatment. Insurance coverage decisions will likely follow positive trial results, making the treatment accessible to even more patients.
The development of ONE-D represents more than just a technical advance—it’s a paradigm shift toward making mental health treatment more patient-centered and accessible. By removing the traditional barriers to TMS therapy while maintaining excellent outcomes, ONE-D could help countless individuals reclaim their lives from depression.
For patients struggling with treatment-resistant depression, ONE-D offers hope wrapped in convenience. The ability to complete an entire course of proven therapy in a single day represents a genuine breakthrough in mental health care—one that could transform how we approach depression treatment for years to come.
The future of depression treatment may indeed be compressed into a single, transformative day. With ONE-D TMS, that future has arrived.